Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 2/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | KDM5A | P29375 | 4/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20205992 | 0.82 | RET (0.39) | SSTR1SSTR4RETKDM5ACCR2 | |
| SCHEMBL20147503 | 0.82 | KDM5A (0.38) | SSTR1SSTR4RETKDM5ACCR2 | |
| SCHEMBL20069725 | 0.82 | RET (0.40) | SSTR1SSTR4RETKDM5A | |
| SCHEMBL20147927 | 0.80 | KDM5A (0.37) | RETKDM5ACCR2 | |
| SCHEMBL20069724 | 0.78 | SSTR4 (0.41) | SSTR1SSTR4RETKDM5A | |
| SCHEMBL15980408 | 0.76 | OGA (0.38) | SSTR1SSTR4SMN1; SMN2 | |
| SCHEMBL18347993 | 0.72 | CHRNB4 (0.36) | SSTR1SSTR4KDM5A | |
| SCHEMBL18361599 | 0.72 | SSTR1 (0.37) | SSTR1SSTR4 | |
| SCHEMBL20069710 | 0.70 | RET (0.36) | SSTR1SSTR4RET | |
| SCHEMBL20148065 | 0.70 | RET (0.38) | SSTR1SSTR4RETKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| WO-2018071454-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | SSTR1 3071/4885SSTR4 2604/4885RET 1/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | SSTR1 3071/4885SSTR4 2604/4885RET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.